TerrAscend Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TRSSF research report →
Range $2.85 – $3
Price Chart
About the company
TerrAscend Corp. operates as a comprehensive cannabis enterprise, engaging in the cultivation, processing, and distribution of cannabis products for both medical and regulated adult recreational markets across Canada and the United States. In addition to its core cannabis operations, the firm also develops and supplies hemp-derived wellness items to retail outlets and crafts specialty cannabis-infused edibles.
- CEO
- Ziad Ghanem
- IPO
- 2017
- Employees
- 972
- HQ
- Mississauga, ON, CA
Get TickerSpark's AI analysis on TRSSF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $601.91M
- P/E
- -5.21
- PEG
- -0.03
- P/S
- 0.51
- P/B
- 1.53
- EV/EBITDA
- 5.08
- Div Yield
- 0.00%
- Gross Margin
- 51.22%
- Op Margin
- 16.53%
- Net Margin
- -8.26%
- ROE
- -25.94%
- ROIC
- -21.13%
Latest fiscal year · YoY change
- Revenue
- $260.56M-15.0%
- Gross Profit
- $136.32M-9.1%
- Op Income
- $42.02M
- Net Income
- $-81,331,000-1.4%
- EPS
- $-0.29-3.6%
- OCF Growth
- -10.6%
- FCF Growth
- +18.7%
- 52W High
- $3.09
- 52W Low
- $1.00
- 50D MA
- $1.66
- 200D MA
- $1.57
- Beta
- 2.00
- RSI (14)
- 58
- Avg Volume
- 140.88K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
TerrAscend posted modest year-over-year growth, stable margins, and strong cash flow, while pointing to further upside from Pennsylvania momentum, New Jersey expansion, and disciplined M&A.· November 5, 2026
- Revenue rose to $68.2 million, up about 5% year over year, with adjusted EBITDA of $17.5 million.
- Gross margin was 52.3%, essentially flat versus 52.1% last year, while free cash flow stayed positive for the 13th straight quarter.
- Pennsylvania was the standout market, with 16.8% revenue growth, 12% same-store sales growth, and 31% wholesale growth.
- New Jersey benefited from the Aunt Mary's acquisition, which adds a fifth dispensary and was described as immediately accretive on EBITDA and free cash flow.
- Management sees more M&A and regulatory upside ahead, including potential benefits from rescheduling, hemp enforcement, and possible tax relief.
Third-quarter 2026 net revenue was $68.2 million versus $65.1 million in the prior-year quarter, up approximately 5%. Gross margin was 52.3% versus 52.1% a year ago, adjusted EBITDA was $17.5 million versus $17.0 million, and net loss from continuing operations was $5.5 million versus $9.9 million. Cash and cash equivalents ended at $42.5 million, operating cash flow was $8.8 million, capital expenditures were $2.7 million, and free cash flow was $6.1 million. For Q4 2026, management expects mid-single-digit year-over-year revenue growth and consistent strong gross margin performance.
Jason Wild emphasized that TerrAscend is executing a disciplined, vertically integrated strategy in its core markets and is prioritizing profitability and cash generation over scale alone. He highlighted the Aunt Mary's acquisition, a renewed buyback authorization, and active M&A discussions, saying the company wants to deploy capital only into accretive deals in markets where it already has infrastructure. He also struck an optimistic tone on regulatory reform, saying rescheduling and hemp enforcement could materially improve profitability and expand the addressable market.
Eric Jackson said Q3 revenue was $68.2 million, gross margin was 52.3%, adjusted EBITDA was $17.5 million, and net loss from continuing operations improved to $5.5 million. He noted G&A rose to $24 million from $21.3 million, mainly due to one-time transaction costs tied to convertible debenture financing and acquisition-related professional fees. He also pointed to $42.5 million of cash, $8.8 million of operating cash flow, $2.7 million of capital expenditures, and $6.1 million of free cash flow, then guided to mid-single-digit revenue growth in Q4 with consistent gross margin strength.
Analysts pressed management on why Pennsylvania is performing so strongly and how much additional capacity remains there. Management said the growth is coming from a mix of brand strength, fresh supply, pricing power, wholesale gains, and retail execution, and added that the facility is about 50% utilized, so it has room to grow without immediate CapEx. Questions also focused on M&A and New Jersey store cadence; management said it is looking in Pennsylvania, Ohio, Florida, Missouri and other markets, but will only do deals that are immediately accretive, and it described losing a Pennsylvania stalking-horse process as evidence of discipline.
The company delivered positive cash flow for the 17th straight quarter and free cash flow for the 13th straight quarter, which supports buybacks and optionality. Core-market execution looks solid, especially in Pennsylvania and New Jersey, and management believes current capacity and new dispensary openings can support further growth. Potential tailwinds from hemp enforcement, rescheduling, and possible tax relief could add upside not reflected in current results.
Growth was still only mid-single digits overall, and gross margin was roughly flat year over year. G&A increased materially because of transaction-related costs, and management acknowledged competitive pressure and price compression in New Jersey. The biggest upside claims depend on execution around M&A, regulatory outcomes, and future adult-use or tax benefits, all of which remain uncertain.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 48.7%
- Shares Outstanding
- 349.95M
- Float Shares
- 170.34M
of shares held by institutions
2 13F filers
Buy/sell ratio 5.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Gofen & Glossberg LLC | 27.50K | 0 |
Held by 2 ETFs
Biggest fund positions in TRSSF by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 24, 23 | J.W. Opportunities Master Fund, Ltd. | other | 0 |
| Dec 1, 22 | Duarte Ira | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TRSSF coverage
Recent articles, reports, and earnings notes.
No research on TRSSF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TRSSF report →Workers at TerrAscend's Apothecarium Dispensary in Phillipsburg, N.J. Vote to Join UFCW Local 360
businesswire.com · Nov 17
TerrAscend Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 5
TerrAscend to Host Third Quarter 2026 Earnings Conference Call
globenewswire.com · Oct 19
TerrAscend to Participate in the ATB Cormark Capital Markets 2026 Life Sciences Fall Institutional Investor Conference
globenewswire.com · Sep 4
TerrAscend Announces Results of Special Meeting of Shareholders
globenewswire.com · Aug 24
TerrAscend Announces Renewal and Replenishment of $10 Million Share Repurchase Program
globenewswire.com · Aug 20
TerrAscend to Host Second Quarter 2026 Earnings Conference Call
globenewswire.com · Jul 16
TerrAscend Signs Agreement to Acquire Fifth Dispensary in New Jersey
globenewswire.com · Jun 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.